Switzerland-based multinational pharma, Novartis, has agreed to acquire Regulus Therapeutics, a publicly traded US-based clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Novartis will commence a tender offer to purchase…
Switzerland: Novartis acquires Regulus Therapeutics for up to US$1.7bn
…
…






